{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000056","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.301501+00:00","generated_at":"2026-06-14T05:56:51.893751+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL","bullets":["67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.","5 of 7 complete responders maintained CR at 6 months; median DOR 23.1 months; 3 patients in remission >24 months, longest >31 months.","No Grade 3+ CRS, ICANS, or GvHD; cytopenias and infections manageable; safety comparable to autologous CAR T.","Pivotal Phase 2 ALPHA2 trial of ALLO-501A enrolling; expected enrollment completion in first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000056","json":"https://secwatch.observer/filing/0001737287-23-000056.json","markdown":"https://secwatch.observer/filing/0001737287-23-000056.md","text":"https://secwatch.observer/filing/0001737287-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/0001737287-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000056/allo-20230603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:56:51.893751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}